Liminatus Pharma (LIMN) Competitors

$0.19 +0.00 (+1.08%)

As of 12:28 PM Eastern

LIMN vs. EVAX, ADXS, PLUR, SNSE, and CRVO

Should you buy Liminatus Pharma stock or one of its competitors? MarketBeat compares Liminatus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liminatus Pharma include Evaxion A/S (EVAX), Ayala Pharmaceuticals (ADXS), Pluri (PLUR), Sensei Biotherapeutics (SNSE), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

How does Liminatus Pharma compare to Evaxion A/S?

Liminatus Pharma (NASDAQ:LIMN) and Evaxion A/S (NASDAQ:EVAX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Evaxion A/S has higher revenue and earnings than Liminatus Pharma. Evaxion A/S is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.15	N/A
Evaxion A/S	$7.53M	4.60	-$7.71M	-$1.47	N/A

In the previous week, Evaxion A/S had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 3 mentions for Evaxion A/S and 2 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.43 beat Evaxion A/S's score of -0.22 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Positive
Evaxion A/S	Neutral

Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 164.74%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Liminatus Pharma's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-402.52%
Evaxion A/S	N/A	-73.56%	-37.45%

11.0% of Evaxion A/S shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Evaxion A/S beats Liminatus Pharma on 9 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Ayala Pharmaceuticals?

Liminatus Pharma (NASDAQ:LIMN) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Liminatus Pharma has higher earnings, but lower revenue than Ayala Pharmaceuticals. Liminatus Pharma is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.15	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

In the previous week, Liminatus Pharma had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for Ayala Pharmaceuticals. Liminatus Pharma's average media sentiment score of 1.43 beat Ayala Pharmaceuticals' score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Positive
Ayala Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-402.52%
Ayala Pharmaceuticals	N/A	N/A	N/A

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Liminatus Pharma and Ayala Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Liminatus Pharma compare to Pluri?

Liminatus Pharma (NASDAQ:LIMN) and Pluri (NASDAQ:PLUR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Pluri has a consensus price target of $12.00, indicating a potential upside of 237.65%. Given Pluri's stronger consensus rating and higher probable upside, analysts clearly believe Pluri is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Liminatus Pharma had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat Liminatus Pharma's score of 1.43 indicating that Pluri is being referred to more favorably in the news media.

Company	Overall Sentiment
Liminatus Pharma	Positive
Pluri	Very Positive

16.6% of Pluri shares are held by institutional investors. 25.9% of Pluri shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Liminatus Pharma has higher earnings, but lower revenue than Pluri. Liminatus Pharma is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.15	N/A
Pluri	$1.34M	28.56	-$22.58M	-$4.92	N/A

Liminatus Pharma has a net margin of 0.00% compared to Pluri's net margin of -1,890.59%.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-402.52%
Pluri	-1,890.59%	N/A	-99.68%

Summary

Pluri beats Liminatus Pharma on 9 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Liminatus Pharma's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-69.97%
Liminatus Pharma	N/A	N/A	-402.52%

In the previous week, Liminatus Pharma had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Liminatus Pharma's score of 1.43 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Very Positive
Liminatus Pharma	Positive

Sensei Biotherapeutics presently has a consensus target price of $40.00, suggesting a potential upside of 94.69%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sensei Biotherapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.15	N/A

Summary

Sensei Biotherapeutics beats Liminatus Pharma on 7 of the 12 factors compared between the two stocks.

How does Liminatus Pharma compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Liminatus Pharma has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	8.61	-$26.97M	-$2.98	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.15	N/A

Liminatus Pharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Liminatus Pharma's return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-96.04%	-82.88%
Liminatus Pharma	N/A	N/A	-402.52%

CervoMed presently has a consensus price target of $23.00, indicating a potential upside of 516.62%. Given CervoMed's stronger consensus rating and higher possible upside, research analysts clearly believe CervoMed is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Liminatus Pharma had 1 more articles in the media than CervoMed. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for CervoMed. CervoMed's average media sentiment score of 1.87 beat Liminatus Pharma's score of 1.43 indicating that CervoMed is being referred to more favorably in the media.

Company	Overall Sentiment
CervoMed	Very Positive
Liminatus Pharma	Positive

25.2% of CervoMed shares are owned by institutional investors. 35.4% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

CervoMed beats Liminatus Pharma on 8 of the 14 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$8.26M	$471.47M	$4.28B	$12.44B
Dividend Yield	N/A	N/A	6.10%	5.30%
P/E Ratio	-1.23	N/A	23.48	25.62
Price / Sales	N/A	360.42	162.17	75.49
Price / Cash	N/A	N/A	51.43	55.34
Price / Book	-0.51	3.15	36.94	6.72
Net Income	-$10.21M	-$81.71M	$114.78M	$333.51M
7 Day Performance	-8.23%	3.44%	3.02%	0.32%
1 Month Performance	2.34%	3.78%	4.60%	4.21%
1 Year Performance	N/A	N/A	16.63%	36.13%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	1.2601 of 5 stars	$0.19 +1.1%	N/A	N/A	$8.39M	N/A	N/A	N/A	Short Interest Decrease Gap Down
EVAX Evaxion A/S	2.9284 of 5 stars	$4.32 -2.1%	$11.00 +154.8%	+158.5%	$36.00M	$7.53M	N/A	60	Earnings Report
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
PLUR Pluri	2.9108 of 5 stars	$3.32 +0.5%	$12.00 +262.0%	-34.4%	$35.72M	$1.34M	N/A	150	Positive News Gap Down
SNSE Sensei Biotherapeutics	2.0899 of 5 stars	$26.07 +0.2%	$40.00 +53.5%	+195.7%	$35.35M	N/A	N/A	40	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. EVAX, ADXS, PLUR, SNSE, and CRVO

How does Liminatus Pharma compare to Evaxion A/S?

Summary

How does Liminatus Pharma compare to Ayala Pharmaceuticals?

Summary

How does Liminatus Pharma compare to Pluri?

Summary

How does Liminatus Pharma compare to Sensei Biotherapeutics?

Summary

How does Liminatus Pharma compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. EVAX, ADXS, PLUR, SNSE, and CRVO

How does Liminatus Pharma compare to Evaxion A/S?

Which has better earnings and valuation, LIMN or EVAX?

Does the media refer more to LIMN or EVAX?

Do analysts rate LIMN or EVAX?

Is LIMN or EVAX more profitable?

Do insiders and institutionals believe in LIMN or EVAX?

Summary

How does Liminatus Pharma compare to Ayala Pharmaceuticals?

Which has better earnings and valuation, LIMN or ADXS?

Does the media refer more to LIMN or ADXS?

Do analysts rate LIMN or ADXS?

Is LIMN or ADXS more profitable?

Do insiders and institutionals believe in LIMN or ADXS?

Summary

How does Liminatus Pharma compare to Pluri?

Do analysts recommend LIMN or PLUR?

Does the media favor LIMN or PLUR?

Do institutionals and insiders believe in LIMN or PLUR?

Which has preferable valuation & earnings, LIMN or PLUR?

Is LIMN or PLUR more profitable?

Summary

How does Liminatus Pharma compare to Sensei Biotherapeutics?

Is SNSE or LIMN more profitable?

Does the media favor SNSE or LIMN?

Do analysts prefer SNSE or LIMN?

Do institutionals and insiders have more ownership in SNSE or LIMN?

Which has higher valuation and earnings, SNSE or LIMN?

Summary

How does Liminatus Pharma compare to CervoMed?

Which has higher valuation and earnings, CRVO or LIMN?

Is CRVO or LIMN more profitable?

Do analysts recommend CRVO or LIMN?

Does the media prefer CRVO or LIMN?

Do institutionals and insiders believe in CRVO or LIMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools